Insulet cuts 2026 U.S. Omnipod and total revenue growth outlook despite beat
Insulet cuts 2026 U.S. Omnipod and total revenue growth outlook despite beating Q2 2026 estimates
- Insulet reduced 2026 U.S. Omnipod revenue growth outlook to 17%-19% from prior 20%-22% range.
- Total 2026 revenue growth guidance trimmed to 20%-22% for the company overall.
- Q2 2026 non-GAAP EPS was $1.66, up 42% YoY and beats estimates.
- Q2 2026 revenue reached $801.7M, up 24% YoY and beats revenue estimates.
- Company raised full-year adjusted EPS growth outlook after reporting stronger-than-expected Q2 2026 results.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.